dihexa cas number | 1401708-83-5 | BGC70883 DIHEXA | Peptide Synthetic |

As with much of the rare disease field, rare vascular disease trials face the same structural challenge: patient populations are small and scattered across countries, making cross-border collaboration essential rather than optional

(Low levels of GH can lead to more body fat and weaker muscles and bones.) GH does this in part by increasing levels of insulin-like growth factor 1 (IGF-1)

Cardiovascular Medicine Several peptides have found successful applications in cardiovascular disease management

Combining different treatment modalities (including lifestyle interventions, pharmacotherapies and bariatric surgery) may support people to achieve individualised long-term goals, maximise health benefits and improve quality of life